Asthma’s Treatment Pipeline Very Strong as More Personalized Medicines Emerge

Share Article

Asthma - Global Drug Forecast and Market Analysis to 2023 is a new pharma market research report announced by Reportstack.

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in Phases II and III of development, and the treatment landscape is moving towards a more personalized approach. Reportstack's report on Asthma - Global Drug Forecast and Market Analysis to 2023 states that the most significant challenge in asthma therapeutics is posed by patients with severe forms of the disease, who remain uncontrolled and have frequent exacerbations, even with the combination of high-dose inhaled corticosteroids (ICSs) and long-acting beta-agonists.

Complete report available at

Key Findings from this Report:

  • The main driver of the enormous expansion of the asthma market will be the uptake of novel targeted biologic agents and once-daily ICS and ICS/LABA therapies in the next-generation inhalers.
  • The major global barrier for the asthma market will be the generic erosion of the leading brands for asthma treatment, such as Advair (fluticasone propionate/salmeterol)and Symbicort (budesonide/formoterol fumarate).
  • Companies are trying to penetrate or dominate the asthma market using two main approaches: 1) developing drugs with different delivery devices to capitalize on long-established off-patent therapies; 2) introducing biologics, in particular, interleukin inhibitors, to treat severe uncontrolled asthma.

The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children.

Valentina Gburcik, Senior Analyst says that the recognition that asthma is a heterogeneous disease, with several subphenotypes in adults and children, means companies are now trying to penetrate the asthma market using two main approaches. Gburcik explains: “One approach is developing drugs with different delivery devices to capitalize on long-established off-patent therapies, while the other is to introduce biologics, particularly interleukin inhibitors, to treat severe uncontrolled asthma.

“The latter approach is clearly reflected in the late-stage asthma pipeline, which consists mainly of targeted biologic therapies. Due to the central role that Th2 cells play in coordinating allergic and asthmatic responses, the receptors and cytokines that stimulate these cells have become key therapeutic targets.”

The analyst states that the shift towards personalized medicine for severe asthmatics marks the beginning of a revolutionary new era in asthma treatment. Gburcik continues: “There are several asthma subphenotypes that are prone to exacerbations, which could be prevented by targeting IL-5 with humanized antibodies. A number of these antibodies are currently being developed, including GlaxoSmithKline’s Bosatria, Teva’s Cinquil and AstraZeneca’s benralizumab, all of which are in Phase III trials.

“In addition, IL-4 and IL-13 have been shown to play a central role in the pathogenesis of some asthma cases, and this has prompted the development of humanized monoclonal antibodies against both these cytokines and the common component of their receptors, the IL-4Rα chain.”

The analyst concludes that while these biologics have shown less impressive results than those targeting IL-5, they have exhibited benefits in specific subgroups of patients. GlaxoSmithKline, Merck & Co, AstraZeneca/MedImmune, Novartis, Roche/Genentech,
Teva, Boehringer Ingelheim, Sunovion and Ono Pharmaceutical Co are the companies mentioned in this report.

More details, table of contents and sample of the report can be obtained by visiting asthma drug forecast report.

Reportstack is one of the leading distributors of market research reports in the world today. Reportstack provides access to over 50,000 company profiles and their strategic information like SWOT analysis, pipeline review reports, chemical industry reports, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack is also a leader in the field of consumer retail research, pharma and healthcare market research reports.


Debora White
Email: debora(at)reportstack(dot)com
Reportstack Market Research
Ph: +1-888-789-6604
United States

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nathan Gold
+1 (888) 789-6604 Ext: 101
Email >

Debora White
Email >
Like >

Follow us on
Visit website